{"disease":{"id":"bardet-biedl-syndrome-bbs","name":"bardet biedl syndrome bbs"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06615011","title":"Bardet Beidle Syndrome in a Syrian Adolescent : a Rare Case Report","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Al Baath University","has_results":false},{"nct_id":"NCT03746522","title":"Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":52,"lead_sponsor_name":"Rhythm Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT05183802","title":"An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)","phase":"","overall_status":"APPROVED_FOR_MARKETING","enrollment_count":null,"lead_sponsor_name":"Rhythm Pharmaceuticals, Inc.","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}